Saturday 17 October 2026
Export BOLT’s income statement to Excel — free account
Bolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.06
0.18
−4.25%
Follow BOLT
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 5 | 4 | 1 | 2 | 4 |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | 0.42 | (1.79) | (3.54) | (7.64) | (12.67) |
P/S ratio |
— | — | 0.00 | 0.00 | 109.10 | 8.93 | 5.57 | 2.66 | 1.33 |
Altman Z″-Score (non-manufacturers) |
— | — | (1.83) | (12.70) | 3.92 | 0.62 | (4.62) | (15.19) | (27.30) |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | (5.31) | (5.31) | (9.14) | (2.85) | (3.07) | (1.42) | (1.43) |
P/B ratio |
— | — | 0.00 | 0.00 | 0.65 | 0.30 | 0.39 | 0.36 | 0.39 |
Price to Tangible BV |
— | — | 0.00 | 0.00 | 0.65 | 0.30 | 0.39 | 0.36 | 0.39 |
EV/Sales |
— | — | 0.00 | 0.00 | (1.14) | (17.02) | (5.19) | (0.61) | 0.35 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.02 | 1.10 | 0.52 | 0.06 | 0.00 |
EV/Operating CF |
— | — | (1.16) | (1.16) | 0.03 | 1.27 | 0.59 | 0.08 | (0.07) |
EV/FCF |
— | — | (1.09) | (1.09) | 0.03 | 1.24 | 0.59 | 0.08 | (0.07) |
Quick Ratio |
— | 4.95 | 4.02 | 2.03 | 8.73 | 7.31 | 5.00 | 3.03 | 3.28 |
Current Ratio |
— | 5.12 | 4.15 | 2.25 | 8.87 | 7.47 | 5.17 | 3.20 | 3.59 |
Net Debt/EBITDA |
— | 1.20 | 0.91 | 0.28 | 1.85 | 1.68 | 1.08 | 0.34 | 0.21 |
Debt/Assets |
0.00% | 0.25% | 14.63% | 20.15% | 7.10% | 8.88% | 10.91% | 23.04% | 35.48% |
Debt/Equity |
— | 0.00 | 0.22 | 26.87 | 0.09 | 0.12 | 0.15 | 0.40 | 0.76 |
Asset Turnover |
— | 0.00 | 0.01 | 0.00 | 0.01 | 0.02 | 0.04 | 0.06 | 0.10 |
Operating CF/Net income |
— | 0.85 | 0.86 | 0.78 | 0.58 | 0.87 | 1.00 | 0.97 | 1.19 |
Capex/Depreciation |
— | 0.00 | (1.52) | (5.06) | (0.61) | (1.06) | 0.08 | (0.13) | 1.43 |
Interest Coverage |
— | (120.51) | — | — | — | — | — | — | — |
| — | 37.51% | 98.68% | 80.54% | (135.83%) | (41.79%) | (48.69%) | (74.28%) | (79.75%) | |
| — | (145.09%) | (94.65%) | (127.86%) | (55.66%) | (32.90%) | (35.71%) | (48.66%) | (42.69%) | |
ROIC |
— | 0.00% | (493.51%) | 0.00% | (67.63%) | (247.18%) | (170.15%) | (142.45%) | (119.22%) |
Return on Tangible Assets |
— | (90.63%) | (106.48%) | (334.04%) | (56.66%) | (56.44%) | (76.71%) | (165.68%) | (144.67%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 12,093.95% | 17,470.56% | 6,004.37% | 1,276.37% | 781.39% | 747.32% | 370.80% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 2,410.23% | 3,920.35% | 1,459.76% | 400.19% | 286.06% | 240.01% | 179.27% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 236.28% | 614.72% | 674.60% | 167.15% | 117.10% | 96.32% | 36.15% |
Graham Net Nets |
— | — | (0.30) | (0.30) | 0.81 | 2.28 | 1.34 | 0.41 | 0.00 |
Graham Number |
— | — | 0.00 | 3,571.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (89.47%) | (89.47%) | (64.08%) | (172.26%) | (157.76%) | (310.28%) | (325.78%) |
Free Cash Flow Yield |
— | — | (73.85%) | (73.85%) | (36.52%) | (153.29%) | (158.98%) | (300.36%) | (380.87%) |
Revenue per Share |
— | 0.00 | 2.16 | 2.20 | 0.76 | 3.07 | 4.17 | 4.03 | 4.12 |
Operating CF per Share |
— | (0.28) | (264.22) | (450.12) | (34.38) | (40.96) | (36.77) | (32.11) | (21.31) |
Capex per Share |
— | 0.00 | (5.10) | (31.04) | (1.41) | (1.05) | (0.11) | 0.06 | 0.48 |
Free Cash Flow per Share |
— | (0.28) | (269.32) | (481.16) | (35.79) | (42.00) | (36.88) | (32.05) | (20.83) |
Cash per Share |
— | 0.39 | 349.31 | 217.30 | 112.19 | 90.42 | 54.05 | 25.20 | 14.82 |
Shareholders Equity per Share |
— | 0.35 | 317.54 | 3.32 | 150.68 | 91.82 | 59.63 | 29.96 | 14.17 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.35 | 317.54 | 3.32 | 150.68 | 91.82 | 59.63 | 29.96 | 14.17 |
Free Cash Flow |
— | (9.87) | (26.85) | (50.57) | (59.40) | (78.46) | (69.73) | (61.18) | (38.96) |
Working Capital |
— | 11.35 | 27.24 | 14.10 | 167.83 | 149.63 | 85.25 | 34.96 | 21.83 |
Capital Expenditures |
— | (0.29) | (0.51) | (3.26) | (2.34) | (1.95) | (0.21) | 0.11 | 0.89 |
Net Current Asset Value |
— | 10.55 | 19.11 | (20.83) | 131.56 | 116.45 | 58.67 | 8.38 | 0.02 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.02 | 1.08 | 0.54 | 0.06 | 0.00 |
Capex to Sales |
— | — | 2.36 | 14.12 | 1.86 | 0.34 | 0.03 | (0.01) | (0.12) |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.21 | 0.24 | 0.16 | 0.62 | 0.29 | (0.53) | (0.27) | 0.50 |
Cash ROIC |
— | (37.83%) | (36.50%) | (155.30%) | (12.96%) | (21.76%) | (30.01%) | (47.70%) | (52.41%) |
Accounts Receivable Turnover |
— | — | 1.38 | 1.48 | 11.89 | 11.46 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 1,078.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | 0.16 | 0.16 | 0.11 | 0.50 | — | — | — |
Average Payables |
— | 1.49 | 1.49 | 1.85 | 2.59 | 3.58 | 3.29 | 2.25 | 1.48 |
Average Assets |
— | 7.99 | 32.21 | 47.49 | 177.13 | 267.76 | 193.80 | 129.71 | 78.19 |
Average Common Equity |
— | (30.89) | (30.89) | (75.40) | 72.59 | 210.81 | 142.12 | 84.97 | 41.85 |
Columns are period end dates